Alerts will be sent to your verified email
Verify EmailJENBURPH
|
Jenburkt Pharma
|
Prevest Denpro
|
Albert David
|
|
|---|---|---|---|
|
Operational Metrics
|
|||
|
Pharmaceuticals
|
|||
|
R&D as a % of Total Sales
|
0.29 % | n/a | 0.84 % |
|
Financials
|
|||
|
5 yr Average ROE
|
18.49 % | 19.0 % | 11.47 % |
|
5yr average Equity Multiplier
|
1.17 | 1.07 | 1.63 |
|
5yr Average Asset Turnover Ratio
|
0.88 | 0.6 | 0.62 |
|
5yr Avg Net Profit Margin
|
18.1 % | 29.64 % | 11.31 % |
|
Price to Book
|
2.53 | 3.66 | 1.02 |
|
P/E
|
14.33 | 22.31 | 0.0 |
|
5yr Avg Cash Conversion Cycle
|
-32.02 Days | 42.6 Days | -77.77 Days |
|
Inventory Days
|
24.72 Days | 36.0 Days | 47.91 Days |
|
Days Receivable
|
48.38 Days | 44.41 Days | 27.87 Days |
|
Days Payable
|
82.6 Days | 39.32 Days | 140.35 Days |
|
5yr Average Interest Coverage Ratio
|
87.2 | 99.71 | 93.73 |
|
5yr Avg ROCE
|
24.44 % | 25.39 % | 14.69 % |
|
5yr Avg Operating Profit Margin
|
22.46 % | 36.91 % | 9.55 % |
|
5 yr average Debt to Equity
|
0.02 | 0.0 | 0.02 |
|
5yr CAGR Net Profit
|
14.21 % | 2.94 % | -4.92 % |
|
5yr Average Return on Assets
|
15.8 % | 17.71 % | 7.03 % |
|
Shareholdings
|
|||
|
Promoter Holding
|
46.64 % | 73.6 % | 62.24 % |
|
Share Pledged by Promoters
|
0.0 | 0.0 | 0.0 |
|
Change in Promoter Holding (3 Yrs)
|
-0.92 % | 0.0 | 0.2 % |
|
Change in Mutual Fund Holding (3 Yrs)
|
0.0 | 0.0 | 0.0 |
|
Jenburkt Pharma
|
Prevest Denpro
|
Albert David
|
|
|---|---|---|---|
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|